Development of sertraline analogues as potential anti-ischemic stroke agents.

Ischemic stroke (IS) is harmful to human health and social development, and there is no medicine available at present. To find the hit compound for treating ischemic stroke, we screened 28 FDA approved nervous system drugs by using an in vitro OGD-induced stroke model. Notably, our in vitro and in vivo studies demonstrated that low-dose sertraline had good neuroprotective activities, while high-dose sertraline showed significant toxicity. Interestingly, the same high-dose sertraline in the control group did not exhibit any obvious toxic effect. Therefore, it is important to modify the structure of sertraline to improve the activity and reduce the toxicity. Stereoisomers of sertraline were first investigated to analyze the influence of stereochemistry on the neuroprotective activities, which showed no obvious difference. Then we evaluated the activity of our previously reported sertraline analogues and found that introducing amide or alkane groups to the amino moiety might be beneficial to enhance the activity and reduce the toxicity. Thus, 10 new analogues were designed, synthesized, and evaluated. Among them, compound OY-201 showed the best safety and neuroprotective activity in both in vitro and in vivo models. Moreover, it exhibited good blood-brain barrier (BBB) permeability, indicating its potential for the development of anti-ischemic stroke drugs. Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Citation

Xin Chen, Hong-Yuan Liu, Sheng-Li Niu, Ting Zhou, Wen Yuan, Peng-Fei Zheng, Qiong Chen, Su-Lan Luo, Jing Gu, Dong-Ting Zhangsun, Qin Ouyang. Development of sertraline analogues as potential anti-ischemic stroke agents. European journal of medicinal chemistry. 2023 Apr 05;252:115273

Mesh Tags

Substances

PMID: 36948129

search → result